Filtered By:
Drug: Rituxan
This page shows you your search results in order of relevance. This is page number 4.
Order by Relevance | Date
Total 5018 results found since Jan 2013.
Updates in the Diagnosis and Management of Linear IgA Disease: A Systematic Review
Conclusion: In cases where preliminary biopsy results are negative and clinical suspicion is high, repeat biopsy and additional diagnostic studies should be used. Patient factors such as age, medical comorbidities, and disease severity play a role in therapeutic selection.PMID:34441024 | PMC:PMC8400507 | DOI:10.3390/medicina57080818
Source: Medicina (Kaunas) - August 27, 2021 Category: Universities & Medical Training Authors: Leah Shin Jeffrey T Gardner Harry Dao Source Type: research
The Efficacy and Safety of Different Dosages of Rituximab for Adults with Immune Thrombocytopenia: A Systematic Review and Meta-Analysis
CONCLUSION: Rituximab was effective and safe for adult patients with ITP. A low-dose rituximab regimen might be an effective alternative to the standard-dose regimen in ITP, as it showed similar CRR, ORR, and SRR at month 12 and was relatively safer with a lower cost.PMID:34660807 | PMC:PMC8514896 | DOI:10.1155/2021/9992086
Source: Biomed Res - October 18, 2021 Category: Research Authors: Yu Dong Ming Yue Mengjiao Hu Source Type: research
Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials
Front Immunol. 2022 Sep 23;13:999704. doi: 10.3389/fimmu.2022.999704. eCollection 2022.ABSTRACTSystemic lupus erythematosus (SLE) is a multisystemic autoimmune disease that frequently affects the kidneys, known as lupus nephritis (LN). Such patients are treated with antimalarials, corticosteroids or immunosuppressive drugs, and more recently, target-specific biological drugs. Although efficacy of these therapies improved SLE-related outcomes, SLE remains associated with higher rates of infections. Here, we performed a comprehensive systemic review of infectious complications in clinical trials covering drug interventions f...
Source: Herpes - October 10, 2022 Category: Infectious Diseases Authors: Stefanie Steiger Louisa Ehreiser Juliane Anders Hans-Joachim Anders Source Type: research
Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease
CONCLUSION: Despite their current wide use, steroids may no longer enjoy first-tier status for TED as more effective and better tolerated medical options become available. Multiple current and emerging therapies, the rationales for which are rooted in theoretical and experimental science, promise better options. These include teprotumumab, rituximab, and tocilizumab. Restoration of immune tolerance could ultimately become the most effective and safe medical management for TED.PMID:36346686 | PMC:PMC9359447 | DOI:10.1210/clinem/dgac328
Source: The Journal of Clinical Endocrinology and Metabolism - November 8, 2022 Category: Endocrinology Authors: Terry J Smith Source Type: research
Myositis: from diagnosis to treatment
DISCUSSION: Helpful resources are the MYOSITIS NETZ ( www.myositis-netz.de ) and the International Myositis Society (iMyoS; www.imyos.org ).PMID:37222759 | PMC:PMC10208204 | DOI:10.1007/s00115-023-01490-8
Source: Der Nervenarzt - May 24, 2023 Category: Neurology Authors: Jens Schmidt Wolfgang M üller-Felber Source Type: research
Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review
CONCLUSION: Both types of the mRNA-vaccines and the AstraZeneca COVID-19 vaccines are highly effective and safe in patients with ARD. However, due to their suboptimal response in some patients, alternative mitigation strategies such as booster vaccines and shielding practices should also be followed. Management of immunomodulatory treatment regimens during the peri vaccination period should be individualized through shared decision making with patients and their attending rheumatologists.PMID:37244811 | PMC:PMC10201317 | DOI:10.1016/j.vaccine.2023.05.048
Source: Vaccine - May 27, 2023 Category: Allergy & Immunology Authors: Anwar I Joudeh Abdu Qaid Lutf Salah Mahdi Gui Tran Source Type: research
Review on the influence of protocol design on clinical outcomes in rheumatoid arthritis treated with rituximab.
CONCLUSIONS: In patients who are nonresponsive to disease-modifying antirheumatic drugs and TNF-α inhibitors, rituximab may be a promising and well-tolerated biologic agent. The capacity of rituximab to produce long-term, sustained remissions could not be evaluated because the duration of the studies was limited to 24 weeks or 48 weeks. Studies with longer periods of observation are warranted.
PMID: 23447479 [PubMed - in process]
Source: The Annals of Pharmacotherapy - March 1, 2013 Category: Drugs & Pharmacology Authors: Shetty S, Fisher MC, Ahmed AR Tags: Ann Pharmacother Source Type: research
